Literature DB >> 3593220

Preferential association of the insulin-like growth factors I and II with metabolically inactive and active carrier-bound complexes in serum.

H J Cornell, G Enberg, A C Herington.   

Abstract

Ion-exchange chromatography of serum on DEAE-Sephadex A-50 using a stepwise NaCl gradient showed that complexes enriched with insulin-like growth factors I and II (IGF-I and IGF-II) could be preferentially eluted. A fraction eluted with 0.075 M-NaCl preferentially contained immunoreactive IGF-I with peak levels appearing in fractions of Mr approx. 110,000. The IGF-I-binding protein complex itself had low bioactivity as measured in a non-suppressible insulin-like (NSILA) bioassay. On conversion to free IGF-I by gel-permeation chromatography on Sephadex G-75 in 1% formic acid, however, the IGF-I did express its intrinsic NSILA bioactivity. In contrast, an IGF-II-enriched complex was eluted from the DEAE-Sephadex with 0.15 M-NaCl. Practically all of the recovered NSILA of the original serum was present in this fraction, in the Mr range 70,000-300,000 with a peak of 150,000. Chromatography on Sephadex G-75 in 1% formic acid separated this high-Mr NSILA into low-Mr (less than 15000) IGF-II and high-Mr acid-stable NSILA-P. The high-Mr IGF-II complex bound to concanavalin A-Sepharose, suggesting that it was a glycoprotein. The results confirm previous reports that a large portion of the NSILA of whole serum can be accounted for by a biologically active acid-dissociable complex. These data show for the first time that this active complex consists of an IGF-II-preferring binding protein. In direct contrast, the IGF-I-preferring complex does not express NSILA bioactivity until the IGF-I is liberated through acidification. The presence of a metabolically active IGF-II complex in serum raises questions as to its possible biological role in the adult.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3593220      PMCID: PMC1147626          DOI: 10.1042/bj2410745

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  32 in total

1.  Somatomedin carrier proteins.

Authors:  G L Smith
Journal:  Mol Cell Endocrinol       Date:  1984-02       Impact factor: 4.102

2.  Evidence for a biologically active, carrier-bound form of non-suppressible insulin-like activity (NSILA) in human serum.

Authors:  H J Cornell; A C Herington
Journal:  Int J Biochem       Date:  1983

3.  Affinity-labeled plasma somatomedin-C/insulinlike growth factor I binding proteins. Evidence of growth hormone dependence and subunit structure.

Authors:  J R Wilkins; A J D'Ercole
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

4.  Insulin-like growth factor characteristics of an acidic non-suppressible insulin-like activity.

Authors:  A C Herington; A D Kuffer
Journal:  Biochem J       Date:  1984-10-01       Impact factor: 3.857

5.  Somatomedin inhibitor in uremia.

Authors:  L S Phillips; A C Fusco; T G Unterman; F del Greco
Journal:  J Clin Endocrinol Metab       Date:  1984-10       Impact factor: 5.958

6.  Immunoreactive IGF-II in serum of healthy subjects and patients with growth hormone disturbances and uraemia.

Authors:  G Enberg; K Hall
Journal:  Acta Endocrinol (Copenh)       Date:  1984-10

7.  The characterization of somatomedin A, isolated by microcomputer-controlled chromatography, reveals an apparent identity to insulin-like growth factor 1.

Authors:  G Enberg; M Carlquist; H Jörnvall; K Hall
Journal:  Eur J Biochem       Date:  1984-08-15

8.  Differentiation between carrier-bound forms of non-suppressible insulin-like activity (NSILA) in serum.

Authors:  H J Cornell; M Bistrin; A C Herington
Journal:  Int J Biochem       Date:  1985

9.  Sequence analysis of somatomedin-C: confirmation of identity with insulin-like growth factor I.

Authors:  D G Klapper; M E Svoboda; J J Van Wyk
Journal:  Endocrinology       Date:  1983-06       Impact factor: 4.736

10.  Comparison of in vivo effects of insulin-like growth factors I and II and of growth hormone in hypophysectomized rats.

Authors:  E Schoenle; J Zapf; C Hauri; T Steiner; E R Froesch
Journal:  Acta Endocrinol (Copenh)       Date:  1985-02
View more
  3 in total

1.  Pharmacodynamic considerations with recombinant human insulin-like growth factor-I in children.

Authors:  Robert J Ferry; Pinchas Cohen; Lorraine E Levitt Katz
Journal:  Horm Res       Date:  2005-05-09

2.  Recognition of insulin-like-growth-factor-binding proteins in serum and amniotic fluid by an antiserum against a low-molecular-mass insulin-like-growth-factor-inhibitor/binding protein.

Authors:  G T Ooi; A C Herington
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

3.  Glycosaminoglycans inhibit formation of the 140 kDa insulin-like growth factor-binding protein complex.

Authors:  R C Baxter
Journal:  Biochem J       Date:  1990-11-01       Impact factor: 3.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.